

Dena M Carbonari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7329089/publications.pdf>

Version: 2024-02-01

29
papers

697
citations

623188

14
h-index

552369

26
g-index

29
all docs

29
docs citations

29
times ranked

1282
citing authors

#	ARTICLE	IF	CITATIONS
1	Validity of ICD-10-CM diagnoses to identify hospitalizations for serious infections among patients treated with biologic therapies. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 899-909.	0.9	11
2	Risk of HCC With Hepatitis B Viremia Among HIV/HBV-Coinfected Persons in North America. <i>Hepatology</i> , 2021, 74, 1190-1202.	3.6	26
3	Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation. <i>Journal of Hepatology</i> , 2021, 75, 1312-1322.	1.8	6
4	HIV RNA, CD4+ Percentage, and Risk of Hepatocellular Carcinoma by Cirrhosis Status. <i>Journal of the National Cancer Institute</i> , 2020, 112, 747-755.	3.0	15
5	Differences in Pathology, Staging, and Treatment between HIV+ and Uninfected Patients with Microscopically Confirmed Hepatocellular Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 71-78.	1.1	4
6	Brief Report: Accuracy of FIB-4 for Cirrhosis in People Living With HIV and Hepatocellular Carcinoma. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 530-534.	0.9	0
7	Concordance of hospitalizations between Clinical Practice Research Datalink and linked Hospital Episode Statistics among patients treated with oral antidiabetic therapies. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 1328-1335.	0.9	5
8	Determinants of Liver Complications Among HIV/Hepatitis B Virus-Coinfected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, 71-80.	0.9	14
9	Validity of diagnostic codes to identify hospitalizations for infections among patients treated with oral antidiabetic drugs. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 1147-1150.	0.9	6
10	Absolute Insurer Denial of Direct-Acting Antiviral Therapy for Hepatitis C: A National Specialty Pharmacy Cohort Study. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy076.	0.4	69
11	Risk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 1172-1181.	0.9	7
12	The Reply. <i>American Journal of Medicine</i> , 2017, 130, e369.	0.6	0
13	Evaluation of methods to estimate missing days' supply within pharmacy data of the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN). <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 115-123.	0.8	5
14	Risk of Acute Liver Injury With Antiretroviral Therapy by Viral Hepatitis Status. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx012.	0.4	6
15	Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes. <i>BMJ Open Diabetes Research and Care</i> , 2017, 5, e000400.	1.2	16
16	Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1035-1043.	2.4	111
17	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 918-919.	2.4	1
18	Oral Azole Antifungal Medications and Risk of Acute Liver Injury, Overall and by Chronic Liver Disease Status. <i>American Journal of Medicine</i> , 2016, 129, 283-291.e5.	0.6	65

#	ARTICLE	IF	CITATIONS
19	Use of demographic and pharmacy data to identify patients included within both the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN). <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 999-1003.	0.9	19
20	Validity of diagnostic codes and laboratory tests of liver dysfunction to identify acute liver failure events. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 676-683.	0.9	17
21	Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs. <i>BMC Pharmacology & Toxicology</i> , 2015, 16, 8.	1.0	6
22	Increased risk of hip fracture associated with dually treated <scp>HIV</scp>/hepatitis <scp>B</scp> virus coinfection. <i>Journal of Viral Hepatitis</i> , 2015, 22, 936-947.	1.0	15
23	Risk of Acute Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hyâ€™s Law and a New Prognostic Model. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2360-2368.	2.4	57
24	Population-Representative Incidence of Drug-Induced Acute Liver Failure Based on an Analysis of an Integrated Health Care System. <i>Gastroenterology</i> , 2015, 148, 1353-1361.e3.	0.6	90
25	Prevalence of diagnosed chronic hepatitis B infection among U.S. Medicaid enrollees, 2000â€™2007. <i>Annals of Epidemiology</i> , 2014, 24, 418-423.	0.9	16
26	Risk of hip fracture associated with untreated and treated chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , 2014, 61, 210-218.	1.8	25
27	Validity of diagnostic codes to identify cases of severe acute liver injury in the U.S. Food and Drug Administration's Miniâ€™Sentinel Distributed Database. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 861-872.	0.9	46
28	Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 1202-1215.	0.9	20
29	Behavioral, Structural and Molecular Changes following Long-term Hippocampal IL-1 β Overexpression in Transgenic Mice. <i>Journal of NeuroImmune Pharmacology</i> , 2012, 7, 145-155.	2.1	19